alexa Lack of worldwide availability of epinephrine autoinjectors for outpatients at risk of anaphylaxis.
Pharmaceutical Sciences

Pharmaceutical Sciences

Journal of Developing Drugs

Author(s): Simons FE

Abstract Share this page

Abstract BACKGROUND: Anaphylaxis is increasing globally and often occurs in the community rather than in a health care setting. Epinephrine, the initial treatment of choice for anaphylaxis, is listed by the World Health Organization as an essential medication; however, the extent of its availability for outpatients is unknown. OBJECTIVE: To determine the availability of epinephrine for use in the first-aid, out-of-hospital treatment of anaphylaxis in different countries. METHODS: We used an investigator-designed, validated survey instrument that was self-administered by members of the World Allergy Organization House of Delegates for 2003 to 2005. Responses were tabulated by country. RESULTS: Completed surveys were received from all 75 representatives of all 39 countries (100\% response rate). At the time of the survey, epinephrine autoinjectors that contained a 0.25- or 0.3-mg dose appropriate for use in adults were available in 56.4\% (95\% confidence interval [CI], 40.8\%-72\%) of these countries. Widespread availability in Europe and availability in countries such as the United States, Canada, and Australia contrasted with limited availability in Asia, South America, and Africa. Autoinjectors that contained a 0.15-mg dose appropriate for use in some children were available in 43.6\% (95\% CI, 28\%-59.2\%) of the 39 countries. Autoinjectors that contained a dose appropriate for use in infants were not available in any country. Costs ranged from 30 US dollars to 110 US dollars. In 27.3\% (95\% CI, 8.7\%-45.9\%) of the countries, no financial assistance from government or private insurance was available to defray the cost. CONCLUSION: This study raises concerns about lack of availability and affordability of epinephrine autoinjectors worldwide for individuals of all ages, especially for the pediatric population. This article was published in Ann Allergy Asthma Immunol and referenced in Journal of Developing Drugs

Relevant Expert PPTs

Relevant Speaker PPTs

Recommended Conferences

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

[email protected]

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

[email protected]

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001 Extn: 9042

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords